GET THE APP

Novel Therapeutics in Lung Cancer | 92573

புற்றுநோயியல் & புற்றுநோய் வழக்கு அறிக்கைகள்

ISSN - 2471-8556

சுருக்கம்

Novel Therapeutics in Lung Cancer

Rana Hadir

In contrast to the widely held belief that a higher BMI reduces the survival and/or incidence of many malignant tumours (such as colonic, pancreatic, and postmenopausal breast cancers), obesity (defined as BMI>30 kg/m2) would be protective for the survival and/or occurrence of a few malignancies, including large B-cell lymphomas, renal, and Non-Small Cell Lung Cancer (NSCLC). This "obesity paradox" has been proposed by epidemiological studies and a recent meta-analysis focusing on NSCLC.